Effects of Burosumab (KRN23), a Human Monoclonal Antibody to FGF23, in Patients with Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS).
Publication
, Conference
De Beur, SJ; Miller, PD; Weber, TJ; Peacock, M; Ruppe, MD; Insogna, K; Luca, D; Theodore-Oklota, C; San Martin, J; Carpenter, T
Published in: JOURNAL OF BONE AND MINERAL RESEARCH
December 1, 2017
Duke Scholars
Published In
JOURNAL OF BONE AND MINERAL RESEARCH
EISSN
1523-4681
ISSN
0884-0431
Publication Date
December 1, 2017
Volume
32
Start / End Page
S280 / S280
Location
Denver, CO
Publisher
WILEY
Conference Name
Annual Meeting of the American-Society-for-Bone-and-Mineral-Research (ASBMR)
Related Subject Headings
- Anatomy & Morphology
- 32 Biomedical and clinical sciences
- 31 Biological sciences
- 11 Medical and Health Sciences
- 09 Engineering
- 06 Biological Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
De Beur, S. J., Miller, P. D., Weber, T. J., Peacock, M., Ruppe, M. D., Insogna, K., … Carpenter, T. (2017). Effects of Burosumab (KRN23), a Human Monoclonal Antibody to FGF23, in Patients with Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS). In JOURNAL OF BONE AND MINERAL RESEARCH (Vol. 32, pp. S280–S280). Denver, CO: WILEY.
De Beur, Suzanne Jan, Paul D. Miller, Thomas J. Weber, Munro Peacock, Mary D. Ruppe, Karl Insogna, Diana Luca, Christina Theodore-Oklota, Javier San Martin, and Thomas Carpenter. “Effects of Burosumab (KRN23), a Human Monoclonal Antibody to FGF23, in Patients with Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS).” In JOURNAL OF BONE AND MINERAL RESEARCH, 32:S280–S280. WILEY, 2017.
De Beur SJ, Miller PD, Weber TJ, Peacock M, Ruppe MD, Insogna K, et al. Effects of Burosumab (KRN23), a Human Monoclonal Antibody to FGF23, in Patients with Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS). In: JOURNAL OF BONE AND MINERAL RESEARCH. WILEY; 2017. p. S280–S280.
De Beur, Suzanne Jan, et al. “Effects of Burosumab (KRN23), a Human Monoclonal Antibody to FGF23, in Patients with Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS).” JOURNAL OF BONE AND MINERAL RESEARCH, vol. 32, WILEY, 2017, pp. S280–S280.
De Beur SJ, Miller PD, Weber TJ, Peacock M, Ruppe MD, Insogna K, Luca D, Theodore-Oklota C, San Martin J, Carpenter T. Effects of Burosumab (KRN23), a Human Monoclonal Antibody to FGF23, in Patients with Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS). JOURNAL OF BONE AND MINERAL RESEARCH. WILEY; 2017. p. S280–S280.
Published In
JOURNAL OF BONE AND MINERAL RESEARCH
EISSN
1523-4681
ISSN
0884-0431
Publication Date
December 1, 2017
Volume
32
Start / End Page
S280 / S280
Location
Denver, CO
Publisher
WILEY
Conference Name
Annual Meeting of the American-Society-for-Bone-and-Mineral-Research (ASBMR)
Related Subject Headings
- Anatomy & Morphology
- 32 Biomedical and clinical sciences
- 31 Biological sciences
- 11 Medical and Health Sciences
- 09 Engineering
- 06 Biological Sciences